Skip to content

Study on the intestinal reachability of L. rhamnosus CRL1505

Study on the intestinal reachability of L. rhamnosus CRL1505 - Study on the intestinal reachability of L. rhamnosus CRL1505

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049069
Enrollment
8
Registered
2024-06-29
Start date
2022-09-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Test food: Vegetable-fruit beverage containing Lactocaseibacillus. rhamnosus CRL1505 strain Intake period: 1 week Daily intake: 100g

Sponsors

Ezaki Glico Co.Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects will be healthy adults who have bowel movements at least 5 times per week.

Exclusion criteria

Exclusion criteria: 1.Those who are regularly using intestinal or laxative medicines (including laxatives) 2.Those who have taken antibiotics within one month of the start of the study 3.Heavy drinkers of alcohol or alcohol dependents 4.Those who regularly consume fermented milk or lactic acid beverages containing lactobacilli or bifidobacteria and foods (supplements, etc.) containing large amounts of oligosaccharides and cannot stop during the study period. 5.Persons suffering from a disease requiring urgent treatment or having a serious complication 6.Those who have a gastrointestinal disease affecting digestion and absorption or a history of surgery 7.Those who have food allergies 8.Those who are pregnant, intend to become pregnant during the study period, or are breastfeeding. 9.Those who are pregnant, intend to become pregnant during the study period, or are breast-feeding. 10.Persons in whom L. rhamnosus was detected as a commensal bacterium.

Design outcomes

Primary

MeasureTime frame
Number of viable Lactocaseibacillus. rhamnosus CRL1505 strains in feces

Countries

Japan

Contacts

Public ContactYuki Ikari

Ezaki Glico Co.Ltd Institute of Product and Technology Development

yuki.ikari@glico.com050-1745-4299

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026